Back to News
Market Impact: 0.42
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial
Source: reuters.com
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
AstraZeneca said its Imfinzi regimen combined with Amgen's targeted immunotherapy Imdelltra significantly improved overall survival in a late-stage trial for first-line extensive-stage small-cell lung cancer. The positive Phase 3 outcome could support a new treatment option and strengthen the commercial outlook for both companies' oncology portfolios.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
AMGN0.72
AZN0.78
More News
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- What next for France as riots rattle markets? Three questions facing investors ahead of more protests
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data
- Best AI Stock Research Tools for Professional Investors